Skip to main content
Caplight Logo









Elegen

Elegen

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://www.elegenbio.com

Last Round

Series B

May 14, 2024

Est. Valuation

$100M

Total Funding Raised

$36.21M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Elegen is a biotechnology company specializing in microfluidics technology that aims to revolutionize synthetic biology through genome engineering and rapid DNA synthesizer development to enhance biomedical progress and DNA sequence testing in healthcare.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

synthetic DNADNA synthesiscell-free DNA synthesisgene synthesisDNA printinglong DNA synthesisplasmid DNAgenetic medicinescell and gene therapysynthetic biologyDNA as a ServicemRNA synthesislinear DNAIVT ready DNANGS verification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elegen Comparables

Compare Elegen with similar companies based on industry and business-model similarity.

Elegen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ansa Biotechnologies
91%
Ribbon Biolabs
89%
Camena Bioscience
83%

Elegen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 14, 2024
GrantSep 23, 2020

Elegen Investors

Notable investors and investment history

Elegen investors
InvestorRounds
Andreessen HorowitzSeries B
Digitalis VenturesSeries B
Triatomic CapitalSeries B
Alix VenturesSeries B
ACVC PartnersSeries B
8VCSeries B
AME Cloud VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 32% month-over-month.

  • Jun 20, 2026

    Monthly visitors increased 47% MoM.

Elegen Filings

Explore SEC and related filing metadata, where available.

Elegen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Elegen's valuation, stock price, and market status.

Is Elegen a public or private company?

Elegen is a private company.

What is the current stock price of Elegen?

Elegen is a private company with no public stock price. No recent secondary market data is available.

How much is Elegen worth (valuation)?

Elegen's valuation is estimated at $100.0M based on funding round data.

Can I buy Elegen stock?

Elegen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Elegen's last funding round?

Elegen's most recent funding round was Series B on May 14, 2024.

Who are the main investors in Elegen?

Key investors in Elegen include Triatomic Capital.

Will Elegen IPO soon?

No public IPO plans have been announced for Elegen.

How can I track Elegen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Elegen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range54
Year Founded2017
Last FundingMay 14, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?